Functional imaging of tumor proteolysis

Annual Review of Pharmacology and Toxicology

Volumn 46, Issue , 2006, Pages 301-315

  Sloane, Bonnie F ^a   Sameni, Mansoureh ^a   Podgorski, Izabela ^a   Cavallo Medved, Dora ^a   Moin, Kamiar ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Invasion; Migration; Organotypic models; Proteolytic pathways; Tumor microenvironment

Indexed keywords

PROTEINASE;

CANCER GROWTH; CANCER INVASION; ENDOTHELIUM CELL; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; IMAGING; INFLAMMATORY CELL; METASTASIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; TUMOR CELL DESTRUCTION;

ANIMALS; COCULTURE TECHNIQUES; DIAGNOSTIC IMAGING; HUMANS; NEOPLASMS; PEPTIDE HYDROLASES;

EID: 33144463387     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.45.120403.095853     Document Type: Review

References (77)

1. Hojilla CV, Mohammed PF, Khokha R. 2003. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br. J. Cancer 89:1817-21
2. Dano K, Behrendt N, Hoyer-Hansen G, Johnsen M, Lund LR, et al. 2005. Plasminogen activation and cancer. Thromb. Haemost. 93:676-81
3. Netzel-Arnett S, Hooper JD, Szabo R, Madison EL, Quigley JP, et al. 2003. Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev. 22:237-58
4. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. 2005. Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol. 23:630-39
5. Jedeszko C, Sloane BF. 2004. Cysteine cathepsins in human cancer. Biol. Chem. 385:1017-27
6. Blobel CP. 2005. ADAMs: key components in EGFR signalling and development. Nat. Rev. Mol. Cell. Biol. 6:32-43
7. Egeblad M, Werb Z. 2002. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. 2:161-74
8. Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C. 2004. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int. J. Dev. Biol. 48:411-24
9. Chau I, Rigg A, Cunningham D. 2003. Matrix metalloproteinase inhibitors-an emphasis on gastrointestinal malignancies. Crit. Rev. Oncol. Hematol. 45:151-76
10. Coussens LM, Fingleton B, Matrisian LM. 2002. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295:2387-92
11. Overall CM, Lopez-Otin C. 2002. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2:657-72
12. Overall CM, McQuibban GA, Clark-Lewis I. 2002. Discovery of chemokine substrates for matrix metalloproteinases by exosite scanning: a new tool for degradomics. Biol. Chem. 383:1059-66
13. Tam EM, Morrison CJ, Wu YI, Stack MS, Overall CM. 2004. Membrane protease proteomics: isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. Proc. Natl. Acad. Sci. USA 101:6917-22
14. Overall CM, Tam EM, Kappelhoff R, Connor A, Ewart T, et al. 2004. Protease degradomics: mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors. Biol. Chem. 385:493-504
15. Rawlings ND, Tolle DP, Barrett AJ. 2004. MEROPS: the peptidase database. Nucleic Acids Res. 32:D160-64 (Database issue)
16. Puente XS, Sanchez LM, Overall CM, Lopez-Otin C. 2003. Human and mouse proteases: a comparative genomic approach. Nat. Rev. Genet. 4:544-58
17. Girands VL, Matrisian LM. 1999. The protease consortium: an alliance to advance the understanding of proteolytic enzymes as therapeutic targets for cancer. Mol. Carcinog. 26:139-42
18. Smith RE, van Frank RM. 1975. The use of amino acid derivatives of 4-methoxy-beta-napthylamine for the assay and subcellular localization of tissue proteinases. Front. Biol. 43:193-249
19. Garrett JR, Kidd A, Kyriacou K, Smith RE. 1985. Use of different derivatives of D-Val-Leu-Arg for studying kallikrein activities in cat submandibular glands and saliva. Histochem. J. 17:805-18
20. Sappino AP, Belin D, Huarte J, Hirschel-Scholz S, Saurat JH, Vassalli JD. 1991. Differential protease expression by cutaneous squamous and basal cell carcinomas. J. Clin. Invest. 88:1073-79
21. Nakamura H, Ueno H, Yamashita K, Shimada T, Yamamoto E, et al. 1999. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res. 59:467-73
22. Sloane BF, Moin K, Sameni M, Tait LR, Rozhin J, Ziegler G. 1994. Membrane association of cathepsin B can be induced by transfection of human breast epithelial cells with c-Ha-ras oncogene. J. Cell Sci. 107:373-84
23. Sameni M, Elliott E, Ziegler G, Fortgens PH, Dennison C, Sloane BF. 1995. Cathepsins B and D are localized at surface of human breast cancer cells. Pathol. Oncol. Res. 1:43-53
24. Sloane BF, Rozhin J, Johnson K, Taylor H, Crissman JD, Honn KV. 1986. Cathepsin B: association with plasma membrane in metastatic tumors. Proc. Natl. Acad. Sci. USA 83:2483-87
25. Cavanaugh PG, Sloane BF, Bajkowski AS, Gasic GJ, Gasic TB, Honn KV. 1983. Involvement of a cathepsin B-like cysteine proteinase in platelet aggregation induced by tumor cells and their shed membrane vesicles. Clin. Exp. Metastasis 1:297-308
26. Campo E, Munoz J, Miquel R, Palacin A, Cardesa A, et al. 1994. Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am. J. Pathol. 145:301-9
27. Lah TT, Buck MR, Honn KV, Crissman JD, Rao NC, et al. 1989. Degradation of laminin by human tumor cathepsin B. Clin. Exp. Metastasis 7:461-68
28. Buck MR, Karustis DG, Day NA, Honn KV, Sloane BF. 1992. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem. J. 282:273-78
29. Emmert-Buck MR, Roth MJ, Zhuang Z, Campo E, Rozhin J, et al. 1994. Increased gelatinase A (MMP-2) and cathepsin B activity in microdissected human colon cancer. Am. J. Pathol. 145:1285-90
30. Hazen LG, Bleeker FE, Lauritzen B, Bahns S, Song J, et al. 2000. Comparative localization of cathepsin B protein and activity in colorectal cancer. J. Histochem. Cytochem. 48:1421-30
31. Dano K, Romer J, Nielsen BS, Bjorn S, Pyke C, et al. 1999. Cancer invasion and tissue remodeling-cooperation of protease systems and cell types. APMIS 107:120-27
32. Koblinski JE, Ahram M, Sloane BF. 2000. Unraveling the role of proteases in cancer. Clin. Chim. Acta 291:113-35
33. Sameni M, Moin K, Sloane BF. 2000. Imaging proteolysis by living human breast cancer cells. Neoplasia 2:496-504
34. Sameni M, Dosescu J, Sloane BF. 2001. Imaging proteolysis by living human glioma cells. Biol. Chem. 382:785-88
35. Ahram M, Sameni M, Qiu R-G, Linebaugh B, Kirn D, Sloane BF. 2000. Rac1-induced endocytosis is associated with intracellular proteolysis during migration through a 3-dimensional matrix. Exp. Cell Res. 260:292-303
36. Sameni M, Dosescu J, Moin K, Sloane BF. 2003. Functional imaging of proteolysis: stromal and inflammatory cells increase tumor proteolysis. Mol. Imaging 2:159-75
37. Podgorski I, Linebaugh BE, Sameni M, Jedeszko C, Bhagat S, et al. 2005. Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer. Neoplasia 7:207-23
38. Cavallo-Medved D, Mai J, Dosescu J, Sameni M, Sloane BF. 2005. Caveolin-1 mediates expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell surface receptors in human colorectal carcinoma cells. J. Cell Sci. 18:1493-503
39. Bogyo M, Verhelst S, Bellingard-Dubouchaud V, Toba S, Greenbaum D. 2000. Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs. Chem. Biol. 7:27-38
40. Friedl P, Wolf K. 2003. Proteolytic and non-proteolytic migration of tumour cells and leucocytes. Biochem. Soc. Symp. 70:277-85
41. Sahai E. 2005. Mechanisms of cancer cell invasion. Curr. Opin. Genet. Dev. 15:87-96
42. Sloane BF. 1996. Suicidal tumor proteases. Nat. Biotech. 14:826-27
43. Chen WT, Chen JM, Parsons SJ, Parsons JT. 1985. Local degradation of fibronectin at sites of expression of the transforming gene product pp60src. Nature 316:156-58
44. Behrendt N. 2004. The urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): membrane proteins engaged in matrix turnover during tissue remodeling. Biol. Chem. 385:103-36
45. Curino AC, Engelholm LH, Yamada SS, Holmbeck K, Lund LR, et al. 2005. Intracellular collagen degradation mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover during malignancy. J. Cell Biol. 169:977-85
46. Schmeichel KL, Bissell MJ. 2003. Modeling tissue-specific signaling and organ function in three dimensions. J. Cell Sci. 116:2377-88
47. Shaw KR, Wrobel CN, Brugge JS. 2004. Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis. J. Mammary Gland Blol. Neoplasia 9:297-310
48. Mai J, Finley R, Waisman DM, Sloane BF. 2000. Human procathepsin B interacts with the annexin II tetramer on the surface of tumor cells. J. Biol. Chem. 275:12806-12
49. Mai J, Waisman DM, Sloane BF. 2000. Cell surface complex of cathepsin B/annexin II tetramer in malignant progression. Biophys. Biochim. Acta 1477:215-30
50. Mayer C, Maaser K, Daryab N, Zanker KS, Brocker EB, Friedl P. 2004. Release of cell fragments by invading melanoma cells. Eur. J. Cell Biol. 83:709-15
51. Brockbank EC, Bridges J, Marshall CJ, Sahai E. 2005. Integrin beta1 is required for the invasive behaviour but not proliferation of squamous cell carcinoma cells in vivo. Br. J. Cancer 17:102-12
52. Sahai E, Marshall CJ. 2003. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signaling and extracellular proteolysis. Nat. Cell Biol. 5:690-92
53. Wolf K, Friedl P. 2005. Functional imaging of pericellular proteolysis in cancer cell invasion. Biochimie 87:315-20
54. Hewitt R, Dano K. 1996. Stromal cell expression of components of matrix-degrading protease systems in human cancer. Enzyme Protein 49:163-73
55. DeClerck YA. 2000. Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer. Eur. J. Cancer 36:1258-68
56. Elenbaas B, Weinberg RA. 2001. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp. Cell Res. 264:169-84
57. Owen JL, Iragavarapu-Charyulu V, Lopez DM. 2004. T cell-derived matrix metalloproteinase-9 in breast cancer: friend or foe? Breast Dis. 20:143-53
58. McCawley LJ, Matrisian LM. 2001. Tumor progression: defining the soil round the tumor seed. Curr. Biol. 11:R25-27
59. Hernandez-Barrantes S, Bernardo M, Toth M, Fridman R. 2002. Regulation of membrane type-matrix metalloproteinases. Semin. Cancer Biol. 12:131-38
60. Quaranta V, Giannelli G. 2003. Cancer invasion: watch your neighbourhood! Tumori 89:343-48
61. Sloane BF, Yan S, Podgorski I, Linebaugh BE, Cher ML, et al. 2005. Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment. Semin. Cancer Biol. 15:149-57
62. Mahmood U, Weissleder R. 2003. Near-infrared optical imaging of proteases in cancer. Mol. Cancer Ther. 2:489-96
63. Funovics M, Weissleder R, Tung CH. 2003. Protease sensors for bioimaging. Anal. Bioanal. Chem. 377:956-63
64. Bogdanov AA Jr, Lin CP, Simonova M, Matuszewski L, Weissleder R. 2002. Cellular activation of the self-quenched fluorescent reporter probe in tumor microenvironment. Neoplasia 4:228-36
65. Chen EI, Kridel SJ, Howard EW, Li W, Godzik A, Smith JW. 2002. A unique substrate recognition profile for matrix metalloproteinase-2. J. Biol. Chem. 277:4485-91
66. Liu S, Bugge TH, Leppla SH. 2001. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J. Biol. Chem. 276:17976-84
67. Liu S, Aaronson H, Mitoba DJ, Leppla SH, Bugge TH. 2003. Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proc. Natl. Acad. Sci USA 100:657-62
68. Ke SH, Coombs GS, Tachias K, Corey DR, Madison EL. 1997. Optimal subsite occupany and design of a selective inhibitor of urokinase. J. Biol. Chem. 272:20456-62
69. Ke SH, Coombs GS, Tachias K, Navre M, Corey DR, Madison EL. 1997. Distinguishing the specificities of closely related proteases. Role of P3 in substrate and inhibitor discrimination between tissue-type plasminogen activator and urokinase. J. Biol. Chem. 272:16603-9
70. Law B, Curino A, Bugge TH, Weissleder R, Tung CH. 2004. Design, synthesis, and characterization of urokinase plasminogen-activator-sensitive near-infrared reporter. Chem. Biol. 11:99-106
71. Law B, Hsiao JK, Bugge TH, Weissleder R, Tung CH. 2005. Optical zymography for specific detection of urokinase plasminogen activator activity in biological samples. Anal. Biochem. 338:151-58
72. McIntyre JO, Fingleton B, Wells KS, Piston DW, Lynch CC, et al. 2004. Development of a novel fluorogenic proteolytic beacon for in vivo detection and imaging of tumour-associated matrix metalloproteinase-7 activity. Biochem. J. 377:617-28
73. Kato D, Boatright KM, Berger AB, Nazif T, Blum G, et al. 2005. Activity-based probes that target diverse cysteine protease families. Nat. Chem. Biol. 1:33-38
74. Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, et al. 2004. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5:443-53
75. 74a. Blum G, Mullins SR, Keren K, Fonovic M, Jedeszko C, et al. 2005. Dynamic imaging of protease activity with fluorescently quenched activity-based probes. Nat. Chem. Biol. In press
76. McIntyre JO, Matrisian LM. 2003. Molecular imaging of proteolytic activity in cancer. J. Cell Biochem. 90:1087-97
77. Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, et al. 2003. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J. Cell Biol. 160:267-77